Bli medlem
Bli medlem

Du är här


Medivir: Good market uptake for Simeprevir during the first quarter 2014

Press Release 15 April 2014

Stockholm, Sweden - Medivir AB (OMX: MVIR) announces a good market
uptake and strong sales development for simeprevir during the first
quarter 2014. In light of this, Johnson & Johnson and Medivir are now
disclosing the simeprevir sales in conjunction with Johnson &
Johnson's first quarter report 2014.

The global first quarter sales (Net sales) of simeprevir amounted to
354 MUSD, of which 291 MUSD were sales in the USA. Medivir's
royalties based on these sales amounted to 162 MSEK (18 MEUR) for the
first quarter.

"We are looking forward with confidence to a continued good sales
development for simeprevir and the increasing royalty revenue
according to our license agreement", said Maris Hartmanis, Medivir's

Medivir will publish its first quarter report on May 8, 2014.

Medivir will host a short telephone conference today.

Conference call

Date: 15 April 2014
Time: 14.45 (CET)

Phone numbers for participants from:

England +44 (0)20 707 532 17
US +1 866 565 2905
Sweden +46 (0)8 619 75 30
Code 946208#

For more information please contact:

Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

Medivir is required under the Securities Markets Act to make the
information in this press release public. The information was
submitted for publication at 13.55 CET on 15 April 2014.

About Simeprevir

Simeprevir is an NS3/4A protease inhibitor jointly developed by
Janssen R&D Ireland and Medivir AB and indicated for the treatment
chronic hepatitis C infection in combination with pegylated
interferon and ribavirin in HCV genotype 1 and 4 infected patients
with compensated liver disease, including cirrhosis.

Janssen is responsible for the global clinical development of
simeprevir and has exclusive, worldwide marketing rights, except in
the Nordic countries. Medivir AB retains marketing rights for
simeprevir in these countries under the marketing authorization held
by Janssen-Cilag International NV. Simeprevir was approved for the
treatment of chronic hepatitis C infection as part of an antiviral
treatment regimen in combination with pegylated interferon and
ribavirin in genotype 1 infected adults with compensated liver
disease, including cirrhosis in September 2013 in Japan, in November
2013 in Canada and the U.S. and in March 2014 in Russia. A Marketing
Authorisation Application was submitted to the European Medicines
Agency (EMA) in April 2013 by Janssen-Cilag International NV seeking
approval of simeprevir for the treatment of genotype 1 or genotype 4
chronic hepatitis C and the Committee for Medicinal Products for
Human Use (CHMP) has adopted a positive opinion, recommending
Marketing Authorisation in the European Union for the use of
simeprevir in combination with other medicinal products for the
treatment of chronic HCV. This application is under review by the

About Medivir

Medivir is an emerging research-based pharmaceutical company focused
on infectious diseases. Medivir has world class expertise in
polymerase and protease drug targets and drug development which has
resulted in a strong infectious disease R&D portfolio. The Company's
key pipeline asset is simeprevir, a novel protease inhibitor for the
treatment of hepatitis C that is being developed in collaboration
with Janssen R&D Ireland. The company is also working with research
and development in other areas, such as bone disorders and
neuropathic pain. Medivir has also a broad product portfolio with
prescription pharmaceuticals in the Nordics.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.